Chemomab Therapeutics Ltd DRC

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$2.39-$9.84
Market Cap
$13.4M
Shares Short
130,446

Financials

See more
Revenue (12 Mos)
$0
Revenue Growth (YoY)
0%
Gross Profit (12 Mos)
$0
Diluted EPS
-$2

News

See more

Yahoo Finance • 3 months ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

Yahoo Finance • 6 months ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Yahoo Finance • 7 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Yahoo Finance • 7 months ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

About

CEO
Dr. Adi Mor George Ph.D.
Address
Building 7, Tel Aviv, Israel, 6158002
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
0